New pneumonia vaccine passes early safety check in small trial
NCT ID NCT07059182
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 31 times
Summary
This early-stage trial tested a single dose of a new whole-cell pneumonia vaccine in 30 healthy adults aged 18 to 49. The main goal was to see if the vaccine is safe and tolerable. Participants were monitored for 30 days after vaccination, and researchers compared side effects between those who got the vaccine and those who got a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rochester Clinical Research
Rochester, New York, 14609, United States
Conditions
Explore the condition pages connected to this study.